An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection

Morbidity and mortality attributed to Clostridium difficile infection (CDI) have increased over the past 20 years. Currently, antibiotics are the only US FDA-approved treatment for primary C. difficile infection, and these are, ironically, associated with disease relapse and the threat of burgeoning...

Descripción completa

Detalles Bibliográficos
Autores principales: Vedantam, Gayatri, Kochanowsky, Joshua, Lindsey, Jason, Mallozzi, Michael, Roxas, Jennifer Lising, Adamson, Chelsea, Anwar, Farhan, Clark, Andrew, Claus-Walker, Rachel, Mansoor, Asad, McQuade, Rebecca, Monasky, Ross Calvin, Ramamurthy, Shylaja, Roxas, Bryan, Viswanathan, V. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134020/
https://www.ncbi.nlm.nih.gov/pubmed/30233548
http://dx.doi.org/10.3389/fmicb.2018.02080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134020/
https://www.ncbi.nlm.nih.gov/pubmed/30233548
http://dx.doi.org/10.3389/fmicb.2018.02080

Ejemplares similares